Pfizer doses first patient in investigational haemophilia drug trial
Pfizer has dosed the first patient in its phase 3 study of marstacimab, an investigational drug being evaluated for the treatment of severe haemophilia A or B with or without inhibitors. Marstacimab is an anti-tissue factor pathway inhibitor (anti-TFPI) in …